Our findings also suggest that CNI (CsA), which is used for the treatment of immune disorders, enhances c-Met activation and augments HGF/c-Met-induced Ras activation in renal cancer cells; and that HNK treatment down-regulates c-Met activation to inhibit CNI-induced renal tumor growth. The gene discussed is MET; the disease is renal carcinoma.